Key result
Chronic nifedipine for achalasia yields low long-term continuation with only ~33% remaining on therapy.
Why the study?
Does nifedipine improve clinical outcomes in patients with initial achalasia?
Observational (n=56)
No
Does nifedipine improve clinical outcomes in patients with initial achalasia?
Medical therapy with nifedipine may be beneficial for a select group of patients with initial achalasia, potentially leading to disease regression in a small subset.
Answers are grounded in this paper and cite their sources.
Chronic nifedipine may benefit select early achalasia cases; leaves open disease modification and should not yet alter practice.
BACKGROUND: The rationale for medical therapy of initial achalasia and the results obtained over the last 20 years in our laboratory are presented. METHODS: Achalasic patients were selected as candidates for medical therapy on the basis of the presence of a slight esophageal dilation (<5 cm) on X-rays and a good manometric response to nifedipine administration. These patients were asked to take 10-20 mg of nifedipine sublingually 30-45 min before each meal for 2 weeks. Chronic medical therapy was continued only in those with an 'excellent' or 'good' clinical response to nifedipine and a lack of severe side effects. X-ray controls were planned every 6 months and manometric examination after the first 6 months. RESULTS: Of the 56 patients selected in the above-mentioned manner, 17 had an insufficient clinical response or severe side effects during the initial trial and did not continue medical therapy. Of the 39 patients who started chronic medical treatment, 13 are still on therapy and 26 stopped after an average of 2.8 years: 17 because they underwent dilation or myotomy; 4 for unknown reasons, and 5 apparently recovered. Esophageal manometry was carried out in 4 of the latter patients and revealed that the achalasic motor pattern had been replaced by a near-normal pattern. CONCLUSIONS: We believe that medical treatment of achalasia should be carried out not only in those patients who cannot undergo invasive procedures or do not respond well to them, but also in patients with initial achalasia selected using the above-mentioned criteria, because regression of the disease could take place in some of them.
No takes yet. Share an insight, caveat, or question.
M. Bortolotti (1999) conducted an observational in Achalasia (n=56). Nifedipine was evaluated on Clinical response and continuation of therapy. Among 56 patients with initial achalasia treated with nifedipine, 39 started chronic therapy, of whom 13 remained on therapy, 17 required invasive procedures, and 5 apparently recovered.
Synapse has enriched 10 related papers. Consider them for comparative context: